Sysmex, Eisai Team Up For Alzheimer’s Diagnostics
Executive Summary
Sysmex is teaming up with fellow Japanese pharma company Eisai to develop a new generation of diagnostic reagents for dementia, including Alzheimer’s disease, which is projected to affect an estimated 65.7 million people globally by 2030 according to the World Health Organization. The companies have entered into a non-exclusive collaboration to create novel IVD products that will enable early detection as well as help physicians in treatment selection and effectiveness monitoring.
You may also be interested in...
Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.